Novartis vows to counter US allegations of price fixing against its Sandoz unit
Novartis said on Monday allegations of price manipulation against its unit Sandoz for generic drugs, produced after the end of its protection under patent rights, in the framework of a US investigation involving 20 pharmaceutical factories without foundation and the Swiss company vowed to face allegations contained in a lawsuit filed by the US government last week .
"We believe that these allegations are groundless and we will deal with them strongly," said Novartis. "Sandoz strongly respects its obligations under antitrust laws. We will remain committed to providing quality and affordable medicines to American patients and be honest in dealing with customers and the government."
The 500-page court case accuses drug manufacturers of ordering to inflate drug prices, sometimes more than 1,000 percent, as well as disrupting competition.
Post a Comment